What does Palatin Technologies do and what are its main business segments?

What were the key takeaways from Palatin Technologies’s earnings call?

What is the revenue and EPS growth rate for Palatin Technologies year over year?

What guidance did Palatin Technologies's management provide for the next earnings period?

What is the market's earnings forecast for Palatin Technologies next quarter?

What were the key takeaways from Palatin Technologies's earnings call?

What is Palatin Technologies's latest dividend and current dividend yield?

What factors drove the changes in Palatin Technologies's revenue and profit?

- **Strategic Milestones Achieved**: $2.3M upfront and $6.5M milestone from BI, $16.9M public offering, and NYSE relisting.
- **Pipeline Progress**: PL7737 IND filing Q2 2026, long-acting peptides entering IND studies Q2 2026, and $307M potential in retinal disease collaboration.
- **Financial Stability**: Net income of $4.7M, 59% expense reduction, and extended cash runway beyond 2026.
- **Market Differentiation**: Next-gen MC4R agonists with reduced side effects and first-in-class positioning in obesity treatment.

**【Management Opening Remarks】**
- **Boehringer Ingelheim Collaboration**: Received upfront payment of $2.3 million and a $6.5 million milestone, with potential for up to $307 million in future milestones and royalties.
- **Public Offering**: Raised $16.9 million (gross) through an 18.2 million share offering, including Series J and K warrants. Series J warrants exercisable at $6.50 if FDA accepts IND by mid-2026; Series K warrants at $8.12 expiring in 2030.
- **NYSE Compliance**: Resumed trading on NYSE American under symbol PTN after regaining compliance.

**【CEO Commentary】**
- **Obesity Pipeline Focus**: 
  - **PL7737**: Oral MC4R agonist with reduced MC1R activity to minimize hyperpigmentation. IND filing expected Q2 2026, with Phase 1 data in Q4 2026.
  - **Long-acting Peptides**: Target weekly or bi-weekly dosing; IND-enabling studies to begin Q2 2026, with first-in-human studies in Q4 2026.
- **Strategic Licensing**: Advanced programs (e.g., PL9643 for dry eye, PL8177 for ulcerative colitis) available for licensing, with BI collaboration as a validation of melanocortin system potential.

**【CFO Financial Commentary】**
- **Q1 2026 Financials**: 
  - Revenue: $8.8 million (vs. $0 prior year) from BI collaboration.
  - Net Income: $4.7 million (vs. $7.8 million loss prior year).
  - Operating Expenses: $4.2 million (59% YoY decline) due to reduced non-core R&D spending.
  - Cash Position: $1.3 million as of Sep 30, 2025, but post-offering, cash runway extended beyond Q4 2026.
- **Liquidity**: Public offering proceeds and expected Series J warrant exercises provide financial stability for obesity program development.

**【Q&A Highlights】**
- **Pipeline Differentiation**: PL7773 and peptides designed for flat PK profiles to maintain efficacy without GI side effects; >100,000-fold MC4R/MC1R selectivity reduces pigmentation risk.
- **Competitive Positioning**: Confident in multi-billion-dollar obesity market potential; focus on first-in-class MC4R-selective compounds.
- **Future Collaborations**: Expect $14.5 million in near-term milestones from BI within 12 months, with active business development for other melanocortin programs.

Palatin Technologies Inc (PTN) Q1 2026 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

PTN

PTN fundamentals

You can ask Aime